News
Prescient Therapeutics enters into OmniCAR cell production agreement with Q-Gen Cell
Q-Gen Cell will produce and deliver the OmniCAR cell lines from its Brisbane facility to be used for Prescient’s upcoming clinical trials.
News
The companies aiming to beat cancer serve up the highlights in the June quarter
Precedence Research suggests the global cancer therapeutics market size is predicted to surpass US$365.99 billion by 2030 and expand growth at a CAGR of 9.1%…
News
Challenging the pace of change in healthcare: Prescient Therapeutics
“The fact of the matter is there are people walking around now who shouldn’t be alive, but they are because of our trials, which is…
News
Prescient Therapeutics’ PTX-100 for peripheral T-cell lymphoma treatment granted US orphan drug status
The designation brings considerable benefits including guaranteed market exclusivity for seven years and a waiver of Prescription Drug User Fee Act fees for orphan drugs,…
News
Prescient Therapeutics granted key US patent for OmniCAR portfolio of therapies
Prescient Therapeutics Ltd (ASX:PTX) has been granted a US patent for its flagship OmniCAR portfolio entitled ‘SpyCatcher and SpyTag: Universal Immune Receptor for T Cells’ that…
News
FIVE at FIVE AU: Iron ore cops a belting and energy prices could stay high until 2025
All the major banks have now lifted interest rates in line with the Reserve Bank of Australia’s cash rate hike of 0.5% yesterday, however that…
News
Prescient Therapeutics delivers new clinic-ready cell therapy technology
Prescient Therapeutics Ltd (ASX:PTX)’s Steven Yatomi-Clarke outlines the company’s oncology treatment vision in a new interview with Proactive. The healthcare stock adopts a portfolio approach when…
RECENT POSTS
Categories
- Article (102)
- Media (6)
- News (295)
- Uncategorized (1)
- Webcast Video (7)